Fulcrum Therapeutics, Inc. - Common Stock (FULC)

MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025.

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths.

What has Wall Street been buzzing about this week? Here are the top 5 buy calls and the top 5 sell calls made by Wall Street's best analysts during the trading week of Sept. 9-13, 2024.

Fulcrum Therapeutics stock drops after Phase 3 REACH trial of losmapimod flops in Facioscapulohumeral Muscular Dystrophy. The company consider suspending the program.

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in the study's success.

FULC stock results show that Fulcrum Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

It's time to start the trading week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!

With the medical care industry always liable for negative surprises, you might as well go for big upside with under-$10 biotech stocks.